CHICAGO (AP) – Alzheimer’s disease may be a risk for older prostate cancer patients given hormone-blocking treatment.
That’s according to a large, U.S. government-funded analysis published Friday.
Previous evidence has been mixed on whether the treatment might be linked with mental decline. But experts say the new results stand out because they’re from a respected national cancer database and the long follow-up was eight years on average.
Among 154,000 older U.S. patients, 13% who received hormone-blocking treatment developed Alzheimer’s, compared with 9% who had other treatment or chose no therapy.
Dementia from strokes and other causes was diagnosed in 22% of patients who got hormone-blocking treatment, versus 16% of the other patients.
The results aren’t proof but experts say they underscore the importance of discussing potential risks and benefits when choosing cancer treatment.
(Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)